Renal Cell Carcinoma as a Metabolic Disease: An Update on Main Pathways, Potential Biomarkers, and Therapeutic Targets
Nicola Antonio di Meo(University of Bari Aldo Moro), Giuseppe Lucarelli(University of Bari Aldo Moro), E. Montanari(University of Milan), Davide Loizzo(University of Bari Aldo Moro), Leonardo Vincenti, Cinzia Bizzoca, Francesco Lasorsa(University of Bari Aldo Moro), Michele Battaglia(University of Bari Aldo Moro), Marco Spilotros(University of Bari Aldo Moro), Pasquale Ditonno(University of Bari Aldo Moro), Felice Crocetto(University of Naples Federico II), Alessandro Stella(University of Bari Aldo Moro), Riccardo Autorino(Cleveland Clinic), Monica Rutigliano(University of Bari Aldo Moro), Savio Domenico Pandolfo(University of L'Aquila), Matteo Ferro(European Institute of Oncology)
Cited by 190
Related Papers
Predictors of Urinary Infections and Urosepsis After Ureteroscopy for Stone Disease: a Systematic Review from EAU Section of Urolithiasis (EULIS)
|Current Urology Reports|2020|167
Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Molecular Basis and Rationale for Their Use in Clinical Practice
|Biomedicines|2023|161
Association of NAFLD and Insulin Resistance with Non Metastatic Bladder Cancer Patients: A Cross-Sectional Retrospective Study
|Journal of Clinical Medicine|2021|131